Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a medical technology issuer focused on minimally invasive, high-definition EEG, ablation, drug delivery and brain stimulation solutions for neurological disorders, NeuroOne uses its SEC reports to present detailed information on its financial condition, operations, risks and material events.
Here you can review NeuroOne’s current reports on Form 8-K, which the company uses to announce events such as quarterly and annual financial results, preliminary revenue figures, FDA 510(k) clearances for devices like the OneRF Trigeminal Nerve Ablation System, capital raising activities and notices related to Nasdaq listing requirements. These filings often incorporate or reference press releases that describe product performance, regulatory milestones and developments in programs including the OneRF Ablation System, spinal cord stimulation initiatives and sEEG-based drug delivery.
In addition to 8-Ks, investors can consult NeuroOne’s periodic reports on Forms 10-Q and 10-K (when available) for comprehensive financial statements, management’s discussion and analysis, and risk factor disclosures tied to its neuromodulation and surgical appliance business. The company has also filed updates related to its at-the-market offering program, distribution agreements and other capital markets activities, which are documented in its SEC submissions.
Stock Titan enhances these NMTC filings with AI-powered summaries that highlight key points, such as revenue trends, gross margin changes, cash position commentary, regulatory updates and listing compliance discussions. Users can quickly identify items like FDA clearance announcements, preliminary annual revenue disclosures and Nasdaq minimum bid price notices, then drill into the full documents for deeper analysis. This page is designed to help investors, analysts and other interested readers efficiently navigate NeuroOne’s official SEC record.
NeuroOne Medical Technologies Corporation is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held April 3, 2026 at its Eden Prairie, MN offices. Stockholders will vote to elect two Class III directors, ratify Baker Tilly as auditor, approve a Board-authorized reverse stock split (a 1-for-2 to 1-for-15 range), approve an amendment to the 2025 Equity Incentive Plan, and authorize adjournments to solicit additional proxies.
The record date for voting is February 20, 2026; 50,693,017 shares of Common Stock were outstanding as of that date. The Board may select the final reverse-split ratio and timing if stockholders approve the range.
NeuroOne Medical Technologies Corporation set April 3, 2026 as the date for its 2026 annual meeting of stockholders. The company will provide the exact time, location, and voting items in a future proxy statement.
Because this date is more than 30 days later than the prior year’s meeting anniversary, stockholder proposals seeking inclusion in the 2026 proxy materials under Rule 14a-8 must be received at the company’s principal executive offices by March 4, 2026.
NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a Form 4 transaction involving company common stock. On this date, 7,376 shares were disposed of at a price of $0.68 per share as a tax-withholding disposition rather than an open-market sale. Following this transaction, Mertens directly owned 153,047 shares of NEUROONE MEDICAL TECHNOLOGIES Corp common stock.
NeuroOne Medical Technologies Corp officer Mark Christianson reported a tax-related share disposition. On February 18, 2026, he disposed of 1,812 shares of common stock at $0.68 per share to cover tax withholding. Following this transaction, he directly owns 228,920 common shares of the company.
NEUROONE MEDICAL TECHNOLOGIES Corp CEO and President David A. Rosa reported a Form 4 transaction involving company common stock. On February 18, 2026, he disposed of 71,325 shares at $0.68 per share in a tax-withholding disposition related to equity compensation, not an open-market sale. After this transaction, he directly owned 1,082,590 common shares.
NeuroOne Medical Technologies Corporation reported fiscal first-quarter 2026 results and raised its outlook for the full year. For the quarter ended December 31, 2025, product revenue was $2.9 million, slightly below $3.3 million a year earlier due to a large initial stocking order in the prior-year period, but up 5.5% from $2.7 million in the previous quarter. Product gross profit was $1.6 million, or 54.2% of revenue.
The company reported a net loss of $1.4 million, or $0.03 per share, compared with net income of $1.8 million, or $0.06 per share, a year ago, when results included $3.0 million of one-time license revenue. As of December 31, 2025, NeuroOne held $3.6 million in cash and cash equivalents, $6.8 million of working capital, and no debt, and believes it is funded through fiscal 2026. Management now expects fiscal 2026 product revenue of at least $10.5 million, at least 17% higher than fiscal 2025.
NeuroOne Medical Technologies reported a net loss of
Cash and cash equivalents were
NeuroOne Medical Technologies Corporation filed an Amendment No. 1 to its annual report to add the Part III sections that would normally come from its proxy, covering board structure, executive pay, ownership and auditor information.
The filing describes a three-class board led by non-executive chairman Paul Buckman, with separate audit, compensation, and nominating and corporate governance committees, all composed of Nasdaq-independent directors other than the CEO. It details 2025 compensation for CEO David Rosa (total $1,154,436), COO Christopher Volker and CFO Ronald McClurg, including base salaries, cash bonuses paid at 94% of target and significant stock option grants.
The amendment also discloses non-employee director retainers (generally $50,000, with $100,000 for the chair) plus equity awards, shows that Merchant Adventure Fund, L.P. beneficially owns 8.3% of common stock, and that all directors and officers as a group hold 11.8%. It notes related-party participation in a 2024 private placement and a 2025 public offering, and lists 2025 audit fees to Baker Tilly US, LLP of $407,111.
NeuroOne Medical Technologies Corporation filed a current report stating that on December 17, 2025 it issued a press release announcing its financial results for the fiscal quarter and year ended September 30, 2025.
The press release is furnished as Exhibit 99.1 and, along with Item 2.02, is treated as furnished rather than filed under the Exchange Act, which affects how it is incorporated into other Securities Act and Exchange Act filings. The company’s common stock trades on the Nasdaq Stock Market under the symbol NMTC.
NeuroOne Medical Technologies Corporation reports its annual update as a neurotechnology company developing thin-film electrodes for brain disorders, chronic pain and drug delivery. It now has four FDA 510(k)-cleared products: Evo cortical and sEEG diagnostic electrodes, the OneRF brain ablation system and the OneRF TN ablation system, with global brain distribution rights for brain applications licensed exclusively to Zimmer. Pipeline programs target spinal cord stimulation, basivertebral nerve ablation and agent-delivering neural electrodes.
The company relies on long-term licenses from WARF and Mayo and an amended Zimmer agreement that added OneRF distribution for a $3 million upfront payment plus potential sales milestones. An April 2025 equity offering of 18.4 million shares at $0.50 generated approximately $8.2 million of net proceeds, yet cash and cash equivalents were about $6.6 million as of September 30, 2025 against an accumulated deficit of $78.6 million. Auditors and management highlight substantial doubt about its ability to continue as a going concern, and Nasdaq has granted only a limited extension to regain the $1.00 minimum bid price.